首页> 外文期刊>American Journal of Physiology >The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats
【24h】

The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats

机译:Ghrelin受体激动剂HM01模仿Ghrelin在弓形核中的神经元效应,并在携带肿瘤大鼠中衰减厌食症症综合征

获取原文
获取原文并翻译 | 示例
           

摘要

The gastric hormone ghrelin positively affects energy balance by increasing food intake and reducing energy expenditure. Ghrelin mimetics are a possible treatment against cancer anorexia-cachexia syndrome (CACS). This study aimed to characterize the action of the nonpeptidergic ghrelin receptor agonist HM01 on neuronal function, energy ho-meostasis and muscle mass in healthy rats and to evaluate its possible usefulness for the treatment of CACS in a rat tumor model. Using extracellular single-unit recordings, we tested whether HM01 mimics the effects of ghrelin on neuronal activity in the arcuate nucleus (Arc). Furthermore, we assessed the effect of chronic HM01 treatment on food intake (FI), body weight (BW), lean and fat volumes, and muscle mass in healthy rats. Using a hepatoma model, we investigated the possible beneficial effects of HM01 on tumor-induced anorexia, BW loss, muscle wasting, and metabolic rate. HM01 (10~(-7)-10~(-6) M) mimicked the effect of ghrelin (10~(-8) M) by increasing the firing rate in 76% of Arc neurons. HM01 delivered chronically for 12 days via osmotic minipumps (50 mug/h) increased FI in healthy rats by 24%, paralleled by increased BW, higher fat and lean volumes, and higher muscle mass. Tumor-bearing rats treated with HM01 had 30% higher FI than tumor-bearing controls and were protected against BW loss. HM01 treatment resulted in higher muscle mass and fat mass. Moreover, tumor-bearing rats reduced their metabolic rate following HM01 treatment. Our studies substantiate the possible therapeutic usefulness of ghrelin receptor agonists like HM01 for the treatment of CACS and possibly other forms of disease-related anorexia and cachexia.
机译:胃激素Ghrelin通过增加食物摄入和减少能源支出来积极影响能量平衡。 Ghrelin模拟物是针对癌症厌食症患者综合征(CACS)的可能治疗方法。本研究旨在表征非专用Ghrelin受体激动剂HM01对健康大鼠神经元功能,能量Ho-Meostasis和肌肉肿块的作用,并评估其在大鼠肿瘤模型中治疗CAC的可能性。使用细胞外单单元录制,我们测试了HM01是否模仿Ghrelin对弓形核(ARC)中神经元活动的影响。此外,我们评估了慢性HM01治疗对食物摄入(FI),体重(BW),瘦和脂肪量以及健康大鼠肌肉肿块的影响。使用肝癌模型,我们调查了HM01对肿瘤诱导的厌食,BW损失,肌肉浪费和代谢率的可能有益效果。 HM01(10〜(-7)-10〜(-6)m)通过增加76%的弧神经元的烧制率来模仿Ghrelin(10〜(-8)m)的效果。 HM01通过渗透MiniPumps(50 mug / h)在健康大鼠中增加24%,并通过增加的BW,脂肪和贫量增加,以及较高的肌肉质量并联。用HM01处理的肿瘤携带的大鼠比肿瘤的控制有30%,并防止BW损失。 HM01治疗导致肌肉质量较高和脂肪质量。此外,在HM01处理后,携带肿瘤大鼠的代谢率降低了它们的代谢率。我们的研究证实了Ghrelin受体激动剂如HM01所可能治疗CAC的可能治疗方法,以及可能其他形式的疾病相关的厌食和恶病症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号